RECORD // Company

In8bio, Inc.

Formerly: Incysus Therapeutics, Inc.

Built 2026-11-22T05:12:21Z from public sources · JSON · Open the company profile

ASK THE RECORDS

Ask

COMPANY

Records for this company (2 joined by official identifier)

Every record below is joined to this company by a hard identifier: its SEC registrant record or its GLEIF ownership tree. Each line says how. Built 2026-11-18 13:42:42. Beta: records that match only by name are held apart until name matching is verified.

Gleif lei (1)
  • IN8BIO, INC. · legal entity in this company's GLEIF ownership tree (LEI 549300H68IVCRKSGSL94)
SEC EDGAR (1)
Records under a former name (1)

The name on these records was this company's name in the past (SEC name history). An old name can also belong to an unrelated organization, so they are shown apart and are not counted above.

Matched by name only, not merged (2)

These records carry the same exact name as this company, but a name alone is not proof, so Seraphix holds them apart until name matching is verified (score due 11-21).

  • In8bio Inc. · Ctgov · same registered legal name as 'IN8BIO, INC.' Possible match based on name, not a shared identifier. Compare the records. Compare
  • IN8BIO, INC. · Ny corps · same registered legal name as 'IN8BIO, INC.' Possible match based on name, not a shared identifier. Compare the records. Compare

2 VALUES · 10-Q · EACH LINKS TO ITS FILING

Latest quarter

Latest report: 10-Q for the period ended 2026-09-30, filed 2026-11-05 · accession 0001193125-26-449876

ItemValuePeriodFormFiledAccessionReport
Net income (loss)$-4,592,0003 months ended 2026-09-3010-Q2026-11-050001193125-26-4498762026-11-22 05:12 UTCReport an error
Cash and cash equivalents$14,150,000at 2026-09-3010-Q2026-11-050001193125-26-4498762026-11-22 05:12 UTCReport an error

Negative as reported in the filing.

Not in this report's XBRL: Revenue, Interest expense.

Values as filed in XBRL (SEC company facts); quarterly values are the filer's 3-month figures, never derived.

IDS

Identifiers

SEC CIK
0001740279
Ticker
INAB
EIN
825462585
CUSIP
45674E208
Record ID
sx:sec:0001740279

OTHER SITES · YOUR CLICK · THEY SHOW THEIR OWN DATA

Open in

Open in…

Each link opens the other site in a new tab, with this company filled in. That site shows its own data under its own terms; Seraphix stores none of it. Seraphix counts clicks per link, nothing about who clicked.

29 FACTS · EACH LINKS TO ITS FILING

Facts

FactValueAs ofSourceRetrievedReport
SEC entity typeoperating2026-11-05SEC EDGAR company profile2026-11-22 05:12 UTCReport an error
SIC industry2836 Biological Products, (No Diagnostic Substances)2026-11-05SEC EDGAR company profile2026-11-22 05:12 UTCReport an error
State of incorporationDE2026-11-05SEC EDGAR company profile2026-11-22 05:12 UTCReport an error
Fiscal year end (MMDD)12312026-11-05SEC EDGAR company profile2026-11-22 05:12 UTCReport an error
Business addressEMPIRE STATE BUILDING, 350 5TH AVENUE, SUITE 5330, NEW YORK, NY, 101182026-11-05SEC EDGAR company profile2026-11-22 05:12 UTCReport an error
ExchangesNasdaq2026-11-05SEC EDGAR company profile2026-11-22 05:12 UTCReport an error
Net income (loss) (fiscal year ended 2025-12-31)$-19,440,0002025-12-3110-K, XBRL NetIncomeLoss2026-11-22 05:12 UTCReport an error
Total assets (at 2025-12-31)$32,282,0002025-12-3110-K, XBRL Assets2026-11-22 05:12 UTCReport an error
Stockholders' equity (at 2025-12-31)$27,558,0002025-12-3110-K, XBRL StockholdersEquity2026-11-22 05:12 UTCReport an error
Cash and cash equivalents (at 2025-12-31)$27,312,0002025-12-3110-K, XBRL CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents2026-11-22 05:12 UTCReport an error
Operating cash flow (fiscal year ended 2025-12-31)$-12,712,0002025-12-3110-K, XBRL NetCashProvidedByUsedInOperatingActivities2026-11-22 05:12 UTCReport an error
Operating lease liabilities (at 2025-12-31)$2,487,0002025-12-3110-K, XBRL OperatingLeaseLiability2026-11-22 05:12 UTCReport an error
Form D total offering amount (D filed 2025-12-30)$40,239,0432025-12-30D2026-11-22 05:12 UTCReport an error
Form D total amount sold (D filed 2025-12-30)$20,119,0492025-12-30D2026-11-22 05:12 UTCReport an error
Form D industry groupBiotechnology2025-12-30D2026-11-22 05:12 UTCReport an error
Form D revenue rangeDecline to Disclose2025-12-30D2026-11-22 05:12 UTCReport an error
Form D date of first sale2025-12-222025-12-30D2026-11-22 05:12 UTCReport an error
8-K Item 2.02, Results of Operations and Financial Condition (filed 2026-11-05)On November 5, 2026, IN8bio, Inc. (the "Company") issued a press release announcing its financial results for the third quarter ended September 30, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Item 2.02, including Exhibit 99.1 hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth…2026-11-05SEC EDGAR 8-K 0001193125-26-449820 (text as filed, excerpt)2026-11-22 05:12 UTCReport an error
8-K Item 2.02, Results of Operations and Financial Condition (filed 2026-08-06)On August 6, 2026, IN8bio, Inc. (the "Company") issued a press release announcing its financial results for the second quarter ended June 30, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Item 2.02, including Exhibit 99.1 hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by…2026-08-06SEC EDGAR 8-K 0001193125-26-337944 (text as filed, excerpt)2026-11-22 05:12 UTCReport an error
Largest institutional holder #1 (13F as filed): Alyeska Investment Group, L.P.$1,331,4902026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 05:12 UTCReport an error
Largest institutional holder #2 (13F as filed): FRANKLIN RESOURCES INC$1,289,4892026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 05:12 UTCReport an error
Largest institutional holder #3 (13F as filed): 683 Capital Management, LLC$1,021,7382026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 05:12 UTCReport an error
Largest institutional holder #4 (13F as filed): Stonepine Capital Management, LLC$980,3552026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 05:12 UTCReport an error
Largest institutional holder #5 (13F as filed): VANGUARD CAPITAL MANAGEMENT LLC$126,5442026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 05:12 UTCReport an error
Largest institutional holder #6 (13F as filed): BIOS Capital Management, LP$114,1492026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 05:12 UTCReport an error
Largest institutional holder #7 (13F as filed): GEODE CAPITAL MANAGEMENT, LLC$102,2982026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 05:12 UTCReport an error
Largest institutional holder #8 (13F as filed): CITADEL ADVISORS LLC$88,9082026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 05:12 UTCReport an error
Largest institutional holder #9 (13F as filed): OPPENHEIMER & CO INC$88,8892026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 05:12 UTCReport an error
Largest institutional holder #10 (13F as filed): VANGUARD FIDUCIARY TRUST CO$62,0442026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 05:12 UTCReport an error

EVERY DATED RECORD, NEWEST FIRST

Timeline

WHAT IS NOT HERE

Gaps

SOURCES AND LICENSE

Sources

CC BY 4.0 -- credit Seraphix Systems.

API

Use this record

Records are free to read and reuse under CC BY 4.0 -- credit Seraphix Systems. The same records as JSON: GET /v1/search?q= and GET /v1/record/<id> (without a key, up to 50 record lookups a day per visitor). No key: single records, pages, feeds and bulk files are free; cross-company search and the live stream cost $0.002 a call via x402. Free key: 100 calls a month, no card. Get a free key or a paid key; send Authorization: Bearer <key>.